DelveInsight’s “Gastric Cancer Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Gastric Cancer market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).
The report covers emerging Gastric Cancer drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current Gastric Cancer treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Gastric Cancer: An Overview
Gastric (stomach) cancer occurs when cancer cells form in the lining of the stomach. There are 5 layers in the stomach wall: mucosa, submucosal, muscularis propria, subserosa and serosa. The location of the tumor and the layers involved play an important role in determining the stage (extent) of the cancer. This can affect a person’s treatment options and prognosis. As the cancer grows from the mucosa into deeper layers, the stage becomes more advanced and demands extensive treatment.
Most of the gastric cancers (about 95-90%) are adenocarcinoma. Gastric adenocarcinoma is of two pathological variants, intestinal and diffuse. The intestinal type is the end result of an inflammatory process that progresses from chronic gastritis to atrophic gastritis and finally to intestinal metaplasia and dysplasia. This type is more common among elderly men, unlike the diffuse type, which is more prevalent among women and individuals under the age of 50. HER2 is an important biomarker that is proven to be an independent prognostic factor. Based on this, GC is of two types: HER2+ Gastric cancer and HER2- Gastric cancer.
Gastric Cancer Market Key Facts
-
Gastric carcinoma (GC) is the fifth most common malignancy worldwide (1,089,103 new cases per year in 2020) and is the third leading cause of cancer deaths (768,793 deaths annually) of all malignancies worldwide. The disease becomes symptomatic in an advanced stage.
-
According to the American Cancer Society’s estimates for gastric cancer in the United States for 2022, there are about 26,380 new cases of stomach cancer (15,900 in men and 10,480 in women) and about 11,090 deaths from this type of cancer (6,690 men and 4,400 women).
-
Although the incidence of gastric cancer is decreasing in Western countries, including the US, there is an increasing incidence of gastroesophageal junction (GEJ) cancer. This is majorly attributable to several potential risk factors such as diet (high in salty and smoked foods) reflux disease, body weight, obesity, H.pylori infection, smoking, etc.
-
According to the recent GLOBOCAN data, in 2020 the estimated number of cases of Gastric cancer in the US, EU4, the UK, and Japan, were 26,259; 50,383; 138,470; and 478,508 cases, respectively.
-
According to the American Cancer Society’s estimates for gastric cancer in the United States for 2022, there are about 26,380 new cases of stomach cancer (15,900 in men and 10,480 in women) and About 11,090 deaths from this type of cancer (6,690 men and 4,400 women).
-
According to the Global Cancer Observatory, in developed countries, gastric cancer is 2.2 times more likely to be diagnosed in males than females. In developing countries, this ratio is 1.83.
-
Among the 7MM, Japan (136,592 cases in 2021) has the highest, and the UK (6,682 cases in 2021) has the lowest number of incident cases of Gastric Cancer.
-
Among the EU4 and the UK countries, Italy leads the pack with an incidence rate of 24.7/100,000, followed by Spain (23.1), Germany (21.6), France (17.0), and the UK (14.2).
The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted market size by analyzing the impact of current and emerging Gastric Cancer pipeline therapies. It also thoroughly assesses the Gastric Cancer market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.
The report gives complete details of the market trend for each marketed Gastric Cancer drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.
Gastric Cancer Epidemiology Assessment
The epidemiology section provides insights into the historical, current, and forecasted Gastric Cancer epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted Gastric Cancer epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pools, future trends, and views of key opinion leaders.
The Report Covers the Gastric Cancer Epidemiology, Segmented as –
Total Diagnosed Incidence Cases of Gastric Cancer in the 7MM [2019-2032]
Stage-specific Cases of Gastric Cancer in the 7MM [2019-2032]
Gender-specific Cases of Gastric Cancer in the 7MM [2019-2032]
Total Treatable Cases of Gastric Cancer in the 7MM [2019-2032]
Biomarker-specific Cases of Gastric Cancer in the 7MM [2019-2032]
Gastric Cancer Drugs Uptake and Pipeline Development Activities
The drug uptake section focuses on the uptake rate of potential drugs recently launched in the Gastric Cancer market or expected to be launched during the study period. The analysis covers the Gastric Cancer market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the market dynamics by drug sales, the most rapid drug uptake, and the reasons behind the maximal use of particular drugs. Additionally, it compares the Gastric Cancer drugs based on their sale and market share.
The report also covers the Gastric Cancer pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key Gastric Cancer companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Learn How the Gastric Cancer Market Will Evolve and Grow by 2032 @
https://www.delveinsight.com/sample-request/gastric-cancer-market
Gastric Cancer Therapeutics Analysis
The clinical practice guidelines for gastric cancer are geography-specific, to accommodate the differences in drugs/diagnostics availability, affordability, and government support across geographies. In the US, the clinical practice guidelines developed by the “National Comprehensive Cancer Network (NCCN)” are adopted country-wide.
Surgery is the primary treatment option for patients with localized gastric cancer. Chemotherapy is the recommended treatment option for the management of unresectable, locally advanced, recurrent, or metastatic gastric cancer. There are several types of chemotherapeutic agents such as ADC (antibody-drug conjugates), immunotherapies, vaccines, and a variety of targeted therapies like anti-HER2+, anti-PD-L1 agents, etc.
There are several targeted therapies approved by the US FDA for the treatment of stomach cancer such as Trastuzumab (Herceptin) by Roche/Genentech/Chugai, Ramucirumab (CYRAMZA), and Pembrolizumab (KEYTRUDA).
To further improve the treatment outlook, several major pharma and biotech companies are developing therapies for Gastric Cancer. Currently, Innovent Biologics is leading the therapeutics market with its Gastric Cancer drug candidates in the most advanced stage of clinical development.
Gastric Cancer Companies Actively Working in the Therapeutics Market Include
Hutchison Medipharma Limited, EMD Serono, Sumitomo Pharma, Jiangsu HengRui Medicine Co., Ltd., LintonPharm Co.,Ltd., Rapa Therapeutics LLC, Jiangsu HengRui Medicine Co., Ltd., Eli Lilly and Company, Janssen Pharmaceutical K.K., Novartis, Genentech, Exelixis, Bristol-Myers Squibb, Pieris Pharmaceuticals, Inc., Pfizer, Leap Therapeutics, CSPC ZhongQi Pharmaceutical, Ellipses Pharma, Amgen, Hanmi Pharmaceutical, Taiho Oncology, Shanghai Henlius Biotech, LianBio LLC, Chengdu Kanghong Biotech, AB Science, Maxinovel, Shanghai Miracogen Inc., Shanghai Miracogen Inc., GlaxoSmithKline, Hoffmann-La Roche, and many others.
Emerging and Marketed Gastric Cancer Therapies Covered in the Report Include:
-
IBI308: Innovent Biologics
-
HLX10: Henlix Biotech
-
Pamiparib: BeiGene
And Many More
Download the Sample Report to Learn More About the Key Companies and Emerging Therapies @
https://www.delveinsight.com/sample-request/gastric-cancer-market
Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Gastric Cancer Competitive Intelligence Analysis
4. Gastric Cancer Market Overview at a Glance
5. Gastric Cancer Disease Background and Overview
6. Gastric Cancer Patient Journey
7. Gastric Cancer Patient Population and Epidemiology Trends (In the US, EU5, and Japan)
8. Gastric Cancer Treatment Algorithm, Current Treatment, and Medical Practices
9. Gastric Cancer Unmet Needs
10. Key Endpoints of Gastric Cancer Treatment
11. Gastric Cancer Marketed Therapies
12. Gastric Cancer Emerging Drugs and Latest Therapeutic Advances
13. Gastric Cancer Seven Major Market Analysis
14. Attribute Analysis
15. Gastric Cancer Market Outlook (In US, EU5, and Japan)
16. Gastric Cancer Companies Active in the Market
17. Gastric Cancer Access and Reimbursement Overview
18. KOL Views on the Gastric Cancer Market
19. Gastric Cancer Market Drivers
20. Gastric Cancer Market Barriers
21. Appendix
22. DelveInsight Capabilities
23. Disclaimer
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Request the Sample PDF to Learn More About the Key Offerings of the Report @
https://www.delveinsight.com/sample-request/gastric-cancer-market
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Other Trending Healthcare Reports by DelveInsight
“Giant-Cell Arteritis Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the Giant-Cell Arteritis market size, share, trends, and growth analysis in the seven major markets (i.e. the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan. Moreover, it also covers the current treatment practices, emerging drugs, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the Giant-Cell Arteritis market.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/